To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers

NCT03610880 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Chinese Volunteers

Interventions

DRUG: TG-2349 (400 mg) plus DAG181 (200 mg)
DRUG: DAG181 (200 mg) plus TG-2349 (400 mg)

Sponsor

Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.

Collaborators

[object Object]